BID | Jotup

The Cannabist Company Announces Normal Course Issuer Bid

Retrieved on:

Tuesday, November 14, 2023

Cannabis, Natural Resources, FSE, Acquisition, Indian stock exchange, BID, NEO, CBOE, Hand, Security (finance)

The Cannabist Company Holdings Inc. (NEO: CBST) (OTCQX: CBSTF) (FSE: 3LP) (“The Cannabist Company” or the “Company”), one of the largest and most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., announced today that its Board of Directors has authorized a normal course issuer bid (the “NCIB”) to purchase up to 15,000,000 of its common shares (“Common Shares”), representing approximately 3.6% of its issued and outstanding Common Shares as at November 9, 2023.

Key Points:

The Cannabist Company Holdings Inc. (NEO: CBST) (OTCQX: CBSTF) (FSE: 3LP) (“The Cannabist Company” or the “Company”), one of the largest and most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., announced today that its Board of Directors has authorized a normal course issuer bid (the “NCIB”) to purchase up to 15,000,000 of its common shares (“Common Shares”), representing approximately 3.6% of its issued and outstanding Common Shares as at November 9, 2023.
The Company has appointed Canaccord Genuity Corp. to coordinate and facilitate purchases under the Bid.
Although the Company presently intends to purchase Common Shares under its NCIB, there can be no assurances that any such purchases will be completed.
The Company will pay the market price for the Common Shares at the time of acquisition and the purchases will be made in accordance with applicable regulatory requirements.

Micromobility.com Inc. Granted Extension for Continued Listing on Nasdaq

Retrieved on:

Thursday, November 9, 2023

Public Transport, Retail, Specialty, Transport, Acquisition, Wheel, BID, Multimedia

Micromobility.com (Nasdaq: MCOM) a leader in innovative urban transportation solutions, today announced it has received an extension from the Nasdaq Hearings Panel to continue its listing on the Nasdaq Capital Market.

Key Points:

Micromobility.com (Nasdaq: MCOM) a leader in innovative urban transportation solutions, today announced it has received an extension from the Nasdaq Hearings Panel to continue its listing on the Nasdaq Capital Market.
This decision is subject to the company meeting specific compliance criteria within designated timeframes.
View the full release here: https://www.businesswire.com/news/home/20231109233516/en/
The Nasdaq Hearings Panel has stipulated that Micromobility.com Inc. must meet all the continued listing requirements, including the Bid Price and Market Value of Listed Securities (MVLS) requirements by the deadline of December 29, 2023.
The company is firmly dedicated to meeting the Panel’s conditions and is strategically positioned to take further actions to ensure ongoing compliance and bolster investor confidence.

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Retrieved on:

Tuesday, December 12, 2023

CNS, Stomatitis, BTK, History, Patient, PCNSL, BID, Symantec Endpoint Protection, Non-Hodgkin lymphoma, Infrared spectroscopy correlation table, NHL, Syncope, Pharmaceutical industry, Curie Institute (Paris)

LEXINGTON, Mass., Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma (PCNSL) patients.

Key Points:

LEXINGTON, Mass., Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma (PCNSL) patients.
"We are very pleased with the initial emavusertib/ibrutinib combination data from the TakeAim Lymphoma study.
As of October 12th, the TakeAim Lymphoma trial has enrolled and treated 19 Non-Hodgkin Lymphoma (NHL) patients, with a combination of emavusertib and ibrutinib; with emavusertib doses ranging from 100 mg to 300 mg BID.
These data underscore the potential of emavusertib to re-sensitize patients to BTKi therapy, marking a significant advancement in Non-Hodgkin Lymphoma treatment.

Lixiang Education Receives Nasdaq Extension to Regain $1 Bid Price Compliance

Retrieved on:

Wednesday, December 6, 2023

BID, The Company, ADS, Letter, Panel, Auction

LISHUI, China, Dec. 6, 2023 /PRNewswire/ -- Lixiang Education Holding Co., Ltd. (the "Company" or NASDAQ: LXEH), a prestigious private education service provider in China, today announced that on November 30, 2023, it received a letter from the Nasdaq Hearings Panel (the "Panel"), indicating the Panel's decision to grant an exception period until January 31, 2024 (the "Exception Period"), for the Company to effect the reverse stock split and thereafter regain compliance with The Nasdaq Stock Market LLC's (the "Nasdaq") Listing Rule 5450(a)(1) (the "Bid Price Rule"), subject to the terms that (1) on or before November 30, 2023, the Company shall obtain its board of directors' approval for a reverse stock split at a ratio that is sufficient to regain and maintain long term compliance with the Bid Price Rule, and the Company shall provide an update to the Panel on the reverse stock split approval on December 1, 2023; (2) on or before January 5, 2024, the Company shall effect a reverse stock split and, thereafter, maintain a $1 closing bid price for a minimum of ten consecutive business days; and (3) on or before January 31, 2024, the Company shall have demonstrated compliance with the Bid Price Rule, by evidencing a closing bid price of $1 or more per share for a minimum of ten consecutive trading sessions.

Key Points:

LISHUI, China, Dec. 6, 2023 /PRNewswire/ -- Lixiang Education Holding Co., Ltd. (the "Company" or NASDAQ: LXEH), a prestigious private education service provider in China, today announced that on November 30, 2023, it received a letter from the Nasdaq Hearings Panel (the "Panel"), indicating the Panel's decision to grant an exception period until January 31, 2024 (the "Exception Period"), for the Company to effect the reverse stock split and thereafter regain compliance with The Nasdaq Stock Market LLC's (the "Nasdaq") Listing Rule 5450(a)(1) (the "Bid Price Rule"), subject to the terms that (1) on or before November 30, 2023, the Company shall obtain its board of directors' approval for a reverse stock split at a ratio that is sufficient to regain and maintain long term compliance with the Bid Price Rule, and the Company shall provide an update to the Panel on the reverse stock split approval on December 1, 2023; (2) on or before January 5, 2024, the Company shall effect a reverse stock split and, thereafter, maintain a $1 closing bid price for a minimum of ten consecutive business days; and (3) on or before January 31, 2024, the Company shall have demonstrated compliance with the Bid Price Rule, by evidencing a closing bid price of $1 or more per share for a minimum of ten consecutive trading sessions.
On November 30, 2023, the Company obtained its board of directors' approval to amend the ratio of American depositary share ("ADS") representing its ordinary shares ("ADS Ratio") from one (1) ADS representing five (5) ordinary share to one (1) ADS representing fifty (50) ordinary shares, and provided an update to the Panel on the ADS Ratio change approval on December 1, 2023.
The Company expects to comply with the rest of the terms within the Exception Period to regain compliance with the Bid Price Rule.
In the event the Company fails to regain compliance with the Bid Price Rule within the Exception Period, its securities will be delisted.

ZK International Group Co., Ltd. Granted Temporary Exception by Nasdaq Hearings Panel

Retrieved on:

Wednesday, November 15, 2023

BID, Exchange, Growth, Cryptocurrency

WENZHOU, China, Nov. 15, 2023 /PRNewswire/ -- ZK International Group Co., Ltd. (Nasdaq: ZKIN) ("ZKIN", "ZK International" or the "Company"), is pleased to announce that the Nasdaq Hearings Panel has granted the company a temporary exception, enabling it to regain compliance with The Nasdaq Stock Market LLC's ("Nasdaq") Listing Rule 5550(a)(2) (the "Bid Price Rule").

Key Points:

WENZHOU, China, Nov. 15, 2023 /PRNewswire/ -- ZK International Group Co., Ltd. (Nasdaq: ZKIN) ("ZKIN", "ZK International" or the "Company"), is pleased to announce that the Nasdaq Hearings Panel has granted the company a temporary exception, enabling it to regain compliance with The Nasdaq Stock Market LLC's ("Nasdaq") Listing Rule 5550(a)(2) (the "Bid Price Rule").
ZK International Group Co., Ltd. has represented to Nasdaq a comprehensive plan to restore compliance with the Bid Price Rule.
The temporary exception extends until January 31, 2024, giving ZK International Group Co., Ltd. a clear timeline to meet these compliance milestones.
The Nasdaq Hearings Panel advised ZK International Group Co., Ltd. that during the exception period, the company must promptly notify Nasdaq of any significant events that could impact its compliance with Nasdaq listing requirements.

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Retrieved on:

Wednesday, November 8, 2023

DSM-IV codes, Food, Diabetes, BID, Insulin resistance, Phase, Cancer, Safety, Patient, Pharmaceutical industry

COVALENT-111 is a multi-site, randomized, double-blind, placebo-controlled Phase I/II study.

Key Points:

COVALENT-111 is a multi-site, randomized, double-blind, placebo-controlled Phase I/II study.
In the completed Phase I portion of the trial, healthy subjects were enrolled in single ascending dose cohorts to ensure safety at the prospective dosing levels for type 2 diabetic patients.
Phase II consists of multiple ascending dose cohorts and dose durations and includes adult patients with type 2 diabetes uncontrolled by current therapies.
Additional information about the Phase I/II clinical trial of BMF-219 in type 2 diabetes can be found at ClinicalTrials.gov using the identifier NCT05731544.

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on:

Wednesday, November 8, 2023

BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or the “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points:

We’ve quickly completed enrollment of the 60-patient lead-in cohort and initial results are expected in early 2024," continued Dr. Sommadossi.
Currently, Atea anticipates providing an update after each of these interim analyses are completed with the first update expected to occur in the first quarter of 2024.
Cash, Cash Equivalents and Marketable Securities: $595.1 million at September 30, 2023 compared to $608.1 million at June 30, 2023.
Income Tax Expense: Income tax expense was $0.2 million for the quarter ended September 30, 2023 compared to a benefit of $3.8 million for the quarter ended September 30, 2022.

MMTEC, Inc. Regains Compliance with Nasdaq Minimum Bid Price Deficiency

Retrieved on:

Wednesday, November 8, 2023

MTC, The Company, Calendar, BID, Letter, Auction

HONG KONG, Nov. 8, 2023 /PRNewswire/ -- MMTEC, Inc. (NASDAQ: MTC) ("MMTEC", "we", "our" or the "Company"), a China-based technology company that provides access to the U.S. financial markets, today announced that the Company received a notification letter (the "Notification Letter") from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement and that the matter is closed.

Key Points:

HONG KONG, Nov. 8, 2023 /PRNewswire/ -- MMTEC, Inc. (NASDAQ: MTC) ("MMTEC", "we", "our" or the "Company"), a China-based technology company that provides access to the U.S. financial markets, today announced that the Company received a notification letter (the "Notification Letter") from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement and that the matter is closed.
As previously disclosed, MMTec, Inc. (the "Company"), received a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") on June 27, 2023, indicating that the Company was not in compliance with Nasdaq Rule 5550(a)(2) (the "Bid Price Rule"), as the closing bid price for the Company's common stock had been below $1.00 per share for the preceding 30 consecutive business days.
In accordance with the Nasdaq Listing Rules, the Company was provided a compliance period of 180 calendar days, or until December 26, 2023, to regain compliance with the Bid Price Rule.
Accordingly, the Company has regained compliance with the Bid Price Rule and the matter is closed.

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

Retrieved on:

Wednesday, November 8, 2023

NEW HAVEN, Conn., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced positive overall survival (OS) data from its Phase 2 trial of BXCL701, the Company's investigational oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype, the most common form of the disease. As of a September 6, 2023 data cutoff, evaluable patients with adenocarcinoma (n=29) showed a median OS of 15.5 months (95% CI 9.6–NR), and a 12-month survival rate of 59%.

Key Points:

As of a September 6, 2023 data cutoff, evaluable patients with adenocarcinoma (n=29) showed a median OS of 15.5 months (95% CI 9.6–NR), and a 12-month survival rate of 59%.
“Therefore, we are highly encouraged by these combination data bearing in mind historical data with checkpoint inhibitor monotherapy.
Approximately 80% of mCRPC cases are of the adenocarcinoma phenotype, which represent approximately 46,128 patients.
The Company is continuing to actively evaluate strategic options for OnkosXcel Therapeutics, including potential financing, strategic partnership, or M&A.

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update

Retrieved on:

Monday, November 6, 2023

Although the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support advancement of VTX958 in plaque psoriasis.

Key Points:

Although the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support advancement of VTX958 in plaque psoriasis.
Accordingly, we will terminate ongoing activities in the Phase 2 plaque psoriasis trial effective immediately.
Based on these results, we have also elected to terminate the ongoing Phase 2 trial of VTX958 in psoriatic arthritis.
ET to discuss the results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis.